Share This Page
Bulk Pharmaceutical API Sources for FOLVITE
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for FOLVITE
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| Sigma-Aldrich | ⤷ Start Trial | 47866_SUPELCO | ⤷ Start Trial |
| Sigma-Aldrich | ⤷ Start Trial | F8758_SIGMA | ⤷ Start Trial |
| Sigma-Aldrich | ⤷ Start Trial | F8798_SIAL | ⤷ Start Trial |
| Sigma-Aldrich | ⤷ Start Trial | F7876_SIGMA | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
FOLVITE API Sourcing Landscape
This report analyzes the global bulk active pharmaceutical ingredient (API) sourcing landscape for FOLVITE (leucovorin calcium). It identifies key manufacturers, assesses manufacturing capabilities, and examines supply chain considerations relevant to pharmaceutical companies and investors.
What is FOLVITE (Leucovorin Calcium)?
FOLVITE is the brand name for leucovorin calcium, an antidote to folic acid antagonists used in chemotherapy. It is also used in combination with fluorouracil to enhance its efficacy in treating colorectal cancer. Leucovorin calcium is a reduced form of folic acid, acting as a metabolic cofactor in DNA synthesis. It is synthesized chemically.
Global API Manufacturing Capacity for Leucovorin Calcium
The production of leucovorin calcium API is concentrated among a limited number of manufacturers globally. These manufacturers often possess integrated capabilities, including the synthesis of key intermediates.
-
Key Manufacturing Regions:
- China
- India
- Europe
-
Major Manufacturers Identified:
- Aarti Industries Ltd. (India): A significant player in pharmaceutical intermediates and APIs, Aarti Industries is a known producer of leucovorin calcium. The company has multiple manufacturing sites in India, with a strong emphasis on backward integration.
- Hubei Biocause Pharmaceutical Co., Ltd. (China): This company is a major producer of folic acid derivatives, including leucovorin calcium. Hubei Biocause operates large-scale fermentation and chemical synthesis facilities.
- Shandong Xinhua Pharmaceutical Company Limited (China): Xinhua Pharmaceutical is a large, established pharmaceutical manufacturer in China with a diverse API portfolio. They are recognized as a supplier of leucovorin calcium.
- Bristol-Myers Squibb (Originator): While not primarily a bulk API supplier in the current market, Bristol-Myers Squibb originally developed and marketed FOLVITE. Their historical involvement signifies the established nature of the API.
- An Additional European Manufacturer: While specific company names are often proprietary or less publicly disclosed for API sourcing, European manufacturers, particularly in countries with established chemical industries like Germany and Switzerland, also contribute to the global supply. These often focus on high-purity grades and adherence to stringent regulatory standards.
Regulatory Compliance and Quality Standards
API manufacturers for leucovorin calcium must adhere to strict global regulatory standards to ensure product quality, safety, and efficacy.
-
Key Regulatory Bodies:
- U.S. Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- Pharmaceuticals and Medical Devices Agency (PMDA) in Japan
- National Medical Products Administration (NMPA) in China
-
Certifications and Audits:
- Good Manufacturing Practices (GMP): Manufacturers must demonstrate compliance with cGMP standards. This includes rigorous quality control, process validation, and documentation.
- Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls for the API.
- Inspections: Facilities are subject to regular inspections by regulatory authorities. Successful inspection outcomes are critical for market access.
Supply Chain Dynamics and Risk Factors
The sourcing of leucovorin calcium API involves several considerations for pharmaceutical companies.
- Supply Concentration: The relatively small number of key manufacturers implies a degree of supply concentration. This can lead to price volatility and potential supply disruptions if a major producer faces issues.
- Geopolitical Risks: Reliance on specific regions, such as China and India, introduces geopolitical risks, including trade policy changes, regulatory shifts, and logistical challenges.
- Quality Assurance: Rigorous vendor qualification processes are essential. This includes site audits, review of quality agreements, and ongoing performance monitoring.
- Intellectual Property: While the basic synthesis of leucovorin calcium is off-patent, specific manufacturing processes or polymorphic forms might be subject to proprietary controls or patents, though less common for established APIs.
- Lead Times: Production cycles and global shipping can result in significant lead times for API orders. Companies must manage inventory and forecasting effectively.
- Price Trends: Historical price data indicates that prices can fluctuate based on raw material costs, energy prices, and global demand. Chinese manufacturers have historically offered competitive pricing, while European and Indian suppliers often focus on premium quality and regulatory assurance.
Manufacturing Process Overview
Leucovorin calcium is synthesized chemically. The process typically involves several steps, starting from folic acid or related precursors.
-
Key Synthesis Stages:
- Reduction of folic acid derivatives.
- Salification to form the calcium salt.
- Purification to meet pharmaceutical standards.
-
Raw Material Sourcing: The availability and cost of key raw materials, such as folic acid, reducing agents, and calcium sources, directly impact API production costs.
Comparative Analysis of Leading Manufacturers
| Manufacturer | Primary Location | Key Strengths | Regulatory Approvals (Examples) |
|---|---|---|---|
| Aarti Industries Ltd. | India | Integrated manufacturing, strong chemical expertise | US FDA, EU GMP |
| Hubei Biocause Pharmaceutical | China | Large-scale production, fermentation capabilities | US FDA, EU GMP |
| Shandong Xinhua Pharmaceutical | China | Established infrastructure, diverse product portfolio | US FDA, EU GMP |
Market Trends and Outlook
The demand for leucovorin calcium API is driven by its established use in oncology and its role as an antidote.
- Oncology Market Growth: The increasing incidence of cancer globally and advancements in chemotherapy regimens that utilize leucovorin calcium support sustained demand.
- Generic Competition: The availability of generic leucovorin calcium products on the market creates a competitive pricing environment for API manufacturers.
- Regulatory Scrutiny: Ongoing regulatory oversight by global health authorities means that manufacturers must continuously invest in quality systems and compliance.
- Supply Chain Resilience: Pharmaceutical companies are increasingly focusing on diversifying their API supplier base to mitigate risks associated with single-source reliance. This could create opportunities for new entrants or for existing suppliers to expand capacity.
Key Takeaways
- The global supply of leucovorin calcium API is concentrated among a few key manufacturers, primarily in China and India, with some European presence.
- Aarti Industries, Hubei Biocause Pharmaceutical, and Shandong Xinhua Pharmaceutical are significant producers.
- Manufacturers must maintain stringent GMP compliance and hold relevant regulatory filings (e.g., DMFs) to serve regulated markets.
- Supply chain risks include concentration, geopolitical factors, and quality assurance requirements.
- Demand is stable, driven by established oncological uses, and influenced by generic competition.
Frequently Asked Questions
What are the primary regions for leucovorin calcium API production?
The primary regions for leucovorin calcium API production are China and India, with a notable presence also in Europe.
Which companies are major manufacturers of leucovorin calcium API?
Major manufacturers include Aarti Industries Ltd. (India), Hubei Biocause Pharmaceutical Co., Ltd. (China), and Shandong Xinhua Pharmaceutical Company Limited (China).
What regulatory standards are critical for leucovorin calcium API manufacturers?
Critical regulatory standards include Good Manufacturing Practices (GMP) as mandated by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and the successful filing and maintenance of Drug Master Files (DMFs).
What are the main risks associated with sourcing leucovorin calcium API?
Main risks include supply concentration among a limited number of manufacturers, geopolitical instability in key production regions, potential quality control issues, and unpredictable lead times.
How does the pricing of leucovorin calcium API typically fluctuate?
Pricing can fluctuate based on raw material costs, energy prices, global demand influenced by oncology treatment trends, and the competitive landscape driven by generic drug availability.
What is the typical manufacturing method for leucovorin calcium?
Leucovorin calcium is manufactured through chemical synthesis, often starting from folic acid or related compounds, involving reduction, salt formation, and purification steps.
Are there any patents impacting the bulk API supply of leucovorin calcium?
While the fundamental synthesis of leucovorin calcium is off-patent, specific manufacturing processes, purification techniques, or polymorphic forms might be subject to proprietary claims or patents, though these are less common for established, high-volume APIs.
Citations
[1] Aarti Industries Ltd. Company Reports. (Accessed [Date]). [2] Hubei Biocause Pharmaceutical Co., Ltd. Product Information. (Accessed [Date]). [3] Shandong Xinhua Pharmaceutical Company Limited. Annual Reports and Product Catalogues. (Accessed [Date]). [4] U.S. Food and Drug Administration. Drug Master Files Database. (Accessed [Date]). [5] European Medicines Agency. Active Substance Master Files (ASMF) Information. (Accessed [Date]). [6] Industry Market Research Reports on Pharmaceutical APIs. (Various Publishers, Accessed [Date]).
More… ↓
